ILLUMINA, INC.

Illumina reported Q2 2026 revenue of $1.16 billion, an increase from $1.06 billion in Q2 2025. However, net income for the quarter decreased to $207 million from $235 million in the prior year. The company also provided an update on the January 30, 2026 acquisition of SomaLogic for $460 million, which is expected to enhance its proteomics market presence and multiomics strategy, contributing to an increase in goodwill and intangible assets.

Illumina announced strong financial results for the second quarter of fiscal year 2026, with revenue reaching $1.16 billion, a 9.5% increase year-over-year. GAAP diluted EPS was $1.35 and non-GAAP diluted EPS was $1.31. Following this performance, the company raised its full-year 2026 revenue guidance to $4.60-$4.64 billion and non-GAAP diluted EPS guidance to $5.30-$5.40. CEO Jacob Thaysen highlighted continued momentum and high demand for NovaSeq X.

Illumina, Inc. announced the appointment of Daniel M. Skovronsky, M.D., Ph.D., to its Board of Directors, effective June 16, 2026. The Board's size was increased from nine to ten members to accommodate the new appointment. Dr. Skovronsky, who is the Chief Scientific and Product Officer of Eli Lilly and Company, brings extensive experience in drug discovery and clinical development to Illumina's board. He qualifies as an independent director and will participate in the non-employee director compensation programs.

Illumina, Inc. held its 2026 annual meeting of stockholders on May 21, 2026. During the meeting, stockholders elected all nine director nominees to the Board of Directors for a one-year term. Additionally, the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending January 3, 2027, was ratified. Stockholders also approved, on an advisory basis, the compensation paid to the company's named executive officers.

Illumina reported Q1 2026 revenue of $1.09 billion, a 4.8% increase year-over-year, with net income rising to $134 million and diluted EPS growing to $0.87. The company completed the acquisition of SomaLogic on January 30, 2026, for a total purchase price of $460 million, aiming to enhance its presence in the proteomics market and advance its multiomics strategy.

Illumina reported strong Q1 2026 financial results with revenue increasing 4.8% to $1.09 billion and non-GAAP diluted EPS reaching $1.15. The company's Board of Directors also authorized a new $1.5 billion share repurchase program, adding to the existing capacity. Following the strong performance, Illumina raised its full-year 2026 revenue and non-GAAP EPS guidance.